Equity / Investment · CIS & Central Asia · Announced 1 Jan 2026
Kazakhstan Ministry of Health → Khan Tengri Biopharma
Kazakhstan's government approved an investment agreement with Khan Tengri Biopharma, co-owned via TengriX by Russia's R-Pharm, for a KZT 103 billion full-cycle biopharma complex making 58 products in the Alatau zone.
Parties: Kazakhstan Ministry of Health (Kazakhstan) → Khan Tengri Biopharma (Kazakhstan)
- Deal type
- Equity / Investment
- Value
- See terms
- Territory
- Kazakhstan – Alatau Special Economic Zone, Almaty region; exports planned to EAEU, CIS and Middle East
- Therapeutic area
- Multi-therapy
- Asset
- Full-cycle biopharmaceutical complex – 58 products (27 INNs) plus APIs
- Announced
- 1 Jan 2026
Our analysis
Why this matters
Kazakhstan's Prime Minister signed a resolution approving an investment agreement between the Ministry of Healthcare and Khan Tengri Biopharma LLP for a full-cycle biopharmaceutical complex in the Alatau Special Economic Zone, Almaty region, worth more than KZT 103 billion. The plant is to make 58 products, including 27 international non-proprietary names for cancer, autoimmune, rare and inflammatory diseases, plus active pharmaceutical ingredients. It is expected to create more than 180 permanent jobs, with part of output for export to EAEU, CIS and Middle Eastern markets.
Corporate records reported by Orda.kz show Khan Tengri Biopharma was registered in March 2025; its co-founder TengriX Ltd. is co-owned by Khan Tengri Capital, Russia's R-Pharm and Sima Ltd. On 2–3 November 2026, the Ministry listed Khan Tengri among eight signed pharma investment contracts totalling KZT 391.3 billion.
The full analysis is free to read with a work email on this page.
Source: Kazinform